Abbott Laboratories' ($ABT) diagnostics unit posted sizable gains in 2014, and the company is continuing to chart positive momentum in the new year with a licensing deal with the Institut Curie. Under the agreement, Abbott will gain exclusive rights for FGFR3 gene mutations for use in bladder cancer, helping the company expand its footprint in molecular diagnostics. Release